News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Access to medicines and treatment news

Show

From To
Pharmaceutical industry
WHO agrees watered-down resolution on transparency in drug costs

Countries at the World Health Organization agreed on Tuesday to push for clearer drug pricing, after watering down a draft resolution that would have also required pharmaceutical firms to disclose the cost of making medicines.

Published
02 June 2019
From
Reuters
Pharmaceutical industry
World Health Assembly Approves Milestone Resolution On Price Transparency

The World Health Assembly today approved a milestone resolution to support greater public disclosure of prices for medicines and other health products – capping a nail-biting series of negotiations that continued until the very moment the measure came to the floor. In a highly unusual move, Germany, the United Kingdom and Hungary “disassociated” themselves from the measure, “Improving the transparency of markets for medicines, vaccines and other health products,” complaining that its far-reaching implications were not fully appreciated, and that the four-month review period since the draft resolution’s submission by lead sponsor Italy had been insufficient.

Published
02 June 2019
From
Health Policy Watch
PrEP programmes and uptake
UK's biggest sexual health clinic has just dropped its PrEP prices

PrEP has become more affordable at London’s leading sexual health clinic. The 56 Dean Street clinic opened its PrEP Shop in February last year and provides the HIV preventative medication for those eligible for NHS care. It will cost as little as £17.50 per month.

Published
02 June 2019
From
Gay Star News
Access to medicines and treatment
High prevalence of stockouts of antiretroviral medicines in South Africa

One in five public health facilities in South Africa were unable to supply at least one antiretroviral (ARV) or tuberculosis (TB) drug on the day they were contacted

Published
23 May 2019
By
Alain Volny-Anne
Pharmaceutical industry
Medicare decides against tighter management of HIV drugs

The Department of Health and Human Services will continue barring Medicare Part D plans from applying the drug utilization management tools prior authorization and step therapy for beneficiaries taking HIV antiretroviral drugs. A rule proposed in November 2018 would have permitted such practices. Gilead voiced opposition to the original proposal, saying physicians need to have the flexibility to prescribe the right medicines for patients.

Published
21 May 2019
From
BioPharma Dive
Access to medicines and treatment
Mexican official resigns as HIV drug shortage sparks outcry

A top Mexican health official said on Thursday that he had resigned amid growing anger over drug shortages that have left hundreds of HIV patients without life-saving medicines.

Published
10 May 2019
From
Reuters
Pharmaceutical industry
Gilead Will Donate Truvada to U.S. for H.I.V. Prevention

Officials at the Department of Health and Human Services said the donation came about “as a result of discussions between the Trump administration and Gilead.” Critics said it would not be enough to end the AIDS epidemic and questioned the company’s motives.

Published
10 May 2019
From
The New York Times
PrEP programmes and uptake
Generic HIV prevention drug coming in 2020, Gilead says

"Gilead reached an agreement with Teva Pharmaceuticals in 2014 to allow the early launch of a generic version of Truvada into the market in 2020, a year earlier than required," wrote Douglas Brooks, Gilead's executive director for community engagement, in an email shared with NBC News by the advocacy group PrEP4All.

Published
09 May 2019
From
CNBC
PrEP programmes and uptake
Official Statement responding to Gilead Sciences’ announcement that it will allow Teva to Manufacture a Generic Version of Truvada

While Gilead’s announcement that generic Truvada will be made available in the United States a year early is a victory for the LGBTQ+ community, for HIV activists, and for U.S. taxpayers, this should only be the beginning. Even their announcement today leaves Gilead with exclusive rights to Truvada as PrEP for another 15 months and Teva as the only generic manufacturer on the U.S. market. This will do little to reduce the price in a way that will increase access and PrEP4All remains suspicious of the terms and lack of transparency surrounding the Teva settlement.

Published
09 May 2019
From
Breakthepatent.org
Pharmaceutical industry
Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency

A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said.

Published
07 May 2019
From
Health Policy Watch
← Prev12345...145Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.